Exelixis is focused on maximizing the opportunity for its two internally discovered compounds, cabozantinib and cobimetinib, to improve care and outcomes for people with cancer.
Discovered by Exelixis, and the focus of our development and commercialization efforts, cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.
Click here to view the cabozantinib pipeline chart.
Cobimetinib is a reversible inhibitor of MEK, also known as mitogen-activated protein kinase. Cobimetinib is being developed by Genentech, a member of the Roche Group, under a collaboration agreement with Exelixis.